Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

4articles mentioning institutions

14institution mentions

1distinct institutions extracted

0%of mentions human-reviewed

Active filtersEntity: ESMO ×

ESMO

This institution is selected. Its supporting articles are shown below.

Articles mentioning ESMO

4 articles · page 1 of 1

Communicating clinical trial information about cancer drug products to patients and healthcare professionals: review of patient-reported outcome messaging

bmjonc · full text · 2026-04-07 · 8 matching annotations

88.5%

FDA ASCO ESMO EMA

…Zykadia), ramucirumab (Cyramza), and nintedanib (Vargatef); the FDA also granted a claim to ceritinib (Zykadia). Limited HCP-facing…

Qualitative study of oncologists’ perceptions on the US Food and Drug Administration approval status and clinical practice guidelines and their impact on local practice patterns in India

bmjonc · full text · 2025-10-22 · 3 matching annotations

82.7%

Tata Hospital National Comprehensive Cancer Network European Society for Medical Oncology Indian Council of Medical Research Indian Society of Medical and Pediatric Oncology ASCO ICMR American Society of Clinical Oncology NCG NCCN+4 more

…ls. (P8) Lack of institutional protocolsMost institutes, unlike Tata Hospital, don’t have their own protocols. (P7) Robustness and timely upd…

Deficient mismatch repair/microsatellite instability-high colorectal cancer: current treatment paradigms, limitations and future perspectives

bmjonc · full text · 2026-02-15 · 2 matching annotations

76.7%

ATOMIC NICHE-2 Northern Ireland Biobank CheckMate 8HW trial European Society of Medical Oncology ESMO

…e that 33% of patients in NICHE-2 had stage II disease, whereas ATOMIC exclusively enrolled patients with stage III disease. Challenge…

Incidence of fractures in patients with solid cancers treated with immune checkpoint inhibitors: a systematic review and meta-analysis of randomised controlled trials

bmjonc · full text · 2025-11-24 · 1 matching annotations

80.0%

ASCO ClinicalTrials.gov ESMO PubMed Embase American Society of Clinical Oncology nivolumab ipilimumab pembrolizumab tremelimumab+6 more

…is issue has been scarce and inconsistent, with guidelines from ASCO and ESMO not currently recognising fractures as a direct conseq…